Drug Type Fusion protein |
Synonyms- |
Target |
Mechanism EPO receptor modulators(Erythropoietin receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 1 | CN | 16 Sep 2022 | |
Breast Cancer | Phase 1 | - | - | |
Colorectal Cancer | Phase 1 | - | - | |
Lung Cancer | Phase 1 | - | - | |
Stomach Cancer | Phase 1 | - | - | |
Hematologic Neoplasms | Preclinical | US | - |
Phase 1 | - | LP-001 1.6 μg/kg(a single s.c. dose) | (eoqibyaskm) = phywttbmdm tbtjqifnmg (mskjscyqhf ) | Positive | 01 Apr 2024 |